|
1
|
Nguyen TT, Hachisuga T, Urabe R, Kurita T,
Kagami S, Kawagoe T, Shimajiri S and Nabeshima K: Significance of
p53 expression in background endometrium in endometrial carcinoma.
Virchows Arch. 466:695–702. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Murali R, Soslow RA and Weigelt B:
Classification of endometrial carcinoma: More than two types.
Lancet Oncol. 15:e268–e278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sharp ZD and Bartke A: Evidence for
down-regulation of phosphoinositide 3-kinase/Akt/mammalian target
of rapamycin (PI3K/Akt/mTOR)-dependent translation regulatory
signaling pathways in Ames dwarf mice. J Gerontol A Biol Sci Med
Sci. 60:293–300. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vanderstraeten A, Luyten C, Verbist G,
Tuyaerts S and Amant F: Mapping the immunosuppressive environment
in uterine tumors: Implications for immunotherapy. Cancer Immunol
Immunother. 63:545–557. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kübler K, Ayub TH, Weber SK, Zivanovic O,
Abramian A, Keyver-Paik MD, Mallmann MR, Kaiser C, Serçe NB, Kuhn W
and Rudlowshi C: Prognostic significance of tumor-associated
macrophages in endometrial adenocarcinoma. Gynecol Oncol.
135:176–183. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Topalian SL, Drake CG and Pardoll DM:
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor
immunity. Curr Opin Immunol. 24:207–212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He C, Qiao H, Jiang H and Sun X: The
inhibitory role of b7-h4 in antitumor immunity: Association with
cancer progression and survival. Clin Dev Immunol. 2011:6958342011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yi KH and Chen L: Fine tuning the immune
response through B7-H3 and B7-H4. Immunol Rev. 229:145–151. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Terness P, Kallikourdis M, Betz AG,
Rabinovich GA, Saito S and Clark DA: Tolerance signaling molecules
and pregnancy: IDO, galectins, and the renaissance of regulatory T
cells. Am J Reprod Immunol. 58:238–254. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ino K, Yoshida N, Kajiyama H, Shibata K,
Yamamoto E, Kidokoro K, Takahashi N, Terauchi M, Nawa A, Nomura S,
et al: Indoleamine 2,3-dioxygenase is a novel prognostic indicator
for endometrial cancer. Br J Cancer. 95:1555–1561. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
de Jong RA, Kema IP, Boerma A, Boezen HM,
van der Want JJ, Gooden MJ, Hollema H and Nijman HW: Prognostic
role of indoleamine 2,3-dioxygenase in endometrial carcinoma.
Gynecol Oncol. 126:474–480. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S,
Kim KM, Park HS, Lee H, Moon WS, Chung MJ, et al: Tumor
infiltrating PD1-positive lymphocytes and the expression of PD-L1
predict poor prognosis of soft tissue sarcomas. PLoS One.
8:e828702013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Taube JM, Anders RA, Young GD, Xu H,
Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL
and Chen L: Colocalization of inflammatory response with B7-h1
expression in human melanocytic lesions supports an adaptive
resistance mechanism of immune escape. Sci Transl Med.
4:127ra372012.PubMed/NCBI
|
|
17
|
Droeser RA, Hirt C, Viehl CT, Frey DM,
Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A,
Rosso R, et al: Clinical impact of programmed cell death ligand 1
expression in colorectal cancer. Eur J Cancer. 49:2233–2242. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lipson EJ, Vincent JG, Loyo M, Kagohara
LT, Luber BS, Wang H, Xu H, Nayar SK, Wang TS, Sidransky D, et al:
PD-L1 expression in the Merkel cell carcinoma microenvironment:
Association with inflammation, Merkel cell polyomavirus and overall
survival. Cancer Immunol Res. 1:54–63. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang Y, Zhao Y, Ran X and Wang C:
Increased expression of herpesvirus entry mediator in
1,25-dihydroxyvitamin D3-treated mouse bone marrow-derived
dendritic cells promotes the generation of
CD4+CD25+Foxp3+regulatory T cells. Mol Med Rep. 9:813–818.
2014.PubMed/NCBI
|
|
20
|
Togno-Peirce C, Nava-Castro K, Terrazas LI
and Morales-Montor J: Sex-associated expression of co-stimulatory
molecules CD80, CD86, and accessory molecules, PDL-1, PDL-2 and
MHC-II, in F480+ macrophages during murine cysticercosis. Biomed
Res Int. 2013:5701582013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rozali EN, Hato SV, Robinson BW, Lake RA
and Lesterhuis WJ: Programmed death ligand 2 in cancer-induced
immune suppression. Clin Dev Immunol. 2012:6563402012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ohigashi Y, Sho M, Yamada Y, Tsurui Y,
Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, et al:
Clinical significance of programmed death-1 ligand-1 and programmed
death-1 ligand-2 expression in human esophageal cancer. Clin Cancer
Res. 11:2947–2953. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M,
Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS, et al: Overexpression
of PD-L1 significantly associates with tumor aggressiveness and
postoperative recurrence in human hepatocellular carcinoma. Clin
Cancer Res. 15:971–979. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kojima M, Murata S, Mekata E, Takebayashi
K, Jaffee EM and Tani T: Fusion protein of mutant B7-DC and Fc
enhances the antitumor immune effect of GM-CSF-secreting whole-cell
vaccine. J Immunother. 37:147–154. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hamanishi J, Mandai M, Iwasaki M, Okazaki
T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N,
et al: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+
T lymphocytes are prognostic factors of human ovarian cancer. Proc
Natl Acad Sci USA. 104:3360–3365. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Karim R, Jordanova ES, Piersma SJ, Kenter
GG, Chen L, Boer JM, Melief CJ and van der Burg SH: Tumor-expressed
B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and
survival of patients with cervical carcinoma. Clin Cancer Res.
15:6341–6347. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cheng L, Jiang J, Gao R, Wei S, Nan F, Li
S and Kong B: B7-H4 expression promotes tumorigenesis in ovarian
cancer. Int J Gynecol Cancer. 19:1481–1486. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen C, Qu QX, Shen Y, Mu CY, Zhu YB,
Zhang XG and Huang JA: Induced expression of B7-H4 on the surface
of lung cancer cell by the tumor-associated macrophages: A
potential mechanism of immune escape. Cancer Lett. 317:99–105.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Miyatake T, Tringler B, Liu W, Liu SH,
Papkoff J, Enomoto T, Torkko KC, Dehn DL, Swisher A and Shroyer KR:
B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid
adenocarcinomas and inversely correlated with tumor T-cell
infiltration. Gynecol Oncol. 106:119–127. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qian Y, Shen L, Cheng L, Wu Z and Yao H:
B7-H4 expression in various tumors determined using a novel
developed monoclonal antibody. Clin Exp Med. 11:163–170. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cindolo L, Benvenuto G, Salvatore P, Pero
R, Salvatore G, Mirone V, Prezioso D, Altieri V, Bruni CB and
Chiariotti L: Galectin-1 and galectin-3 expression in human bladder
transitional-cell carcinomas. Int J Cancer. 84:39–43. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Demydenko D and Berest I: Expression of
galectin-1 in malignant tumors. Exp Oncol. 31:74–79.
2009.PubMed/NCBI
|
|
33
|
Saussez S, Lorfevre F, Lequeux T, Laurent
G, Chantrain G, Vertongen F, Toubeau G, Decaestecker C and Kiss R:
The determination of the levels of circulating galectin-1 and −3 in
HNSCC patients could be used to monitor tumor progression and/or
responses to therapy. Oral Oncol. 44:86–93. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim MK, Sung CO, Do IG, Jeon HK, Song TJ,
Park HS, Lee YY, Kim BG, Lee JW and Bae DS: Overexpression of
Galectin-3 and its clinical significance in ovarian carcinoma. Int
J Clin Oncol. 16:352–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
van den Brûle F, Califice S, Garnier F,
Fernandez PL, Berchuck A and Castronovo V: Galectin-1 accumulation
in the ovary carcinoma peritumoral stroma is induced by ovary
carcinoma cells and affects both cancer cell proliferation and
adhesion to laminin-1 and fibronectin. Lab Invest. 83:377–386.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Stewart CJ and Crook ML: Galectin-3
expression in uterine endometrioid adenocarcinoma: comparison of
staining in conventional tumor glands and in areas of MELF pattern
myometrial invasion. Int J Gynecol Pathol. 29:555–561. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
van den Brule FA, Buicu C, Berchuck A,
Bast RC, Deprez M, Liu FT, Cooper DN, Pieters C, Sobel ME and
Castronovo V: Expression of the 67-kD laminin receptor, galectin-1,
and galectin-3 in advanced human uterine adenocarcinoma. Hum
Pathol. 27:1185–1191. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Brustmann H, Riss D and Naudé S:
Galectin-3 expression in normal, hyperplastic, and neoplastic
endometrial tissues. Pathol Res Pract. 199:151–158. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ege CB, Akbulut M, Zekioğlu O and Ozdemir
N: Investigation of galectin-3 and heparanase in endometrioid and
serous carcinomas of the endometrium and correlation with known
predictors of survival. Arch Gynecol Obstet. 284:1231–1239. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mylonas I, Mayr D, Walzel H, Shabani N,
Dian D, Kuhn C, Kunze S, Jeschke U and Friese K: Mucin 1,
Thomsen-Friedenreich expression and galectin-1 binding in
endometrioid adenocarcinoma: An immunohistochemical analysis.
Anticancer Res. 27:1975–1980. 2007.PubMed/NCBI
|
|
41
|
Howitt BE, Shukla SA, Sholl LM,
Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC,
D'Andrea AD, Wu CJ, et al: Association of polymerase e-mutated and
microsatellite-instable endometrial cancers with neoantigen load,
number of tumor-Infiltrating lymphocytes, and expression of PD-1
and PD-L1. JAMA Oncol. Jul 9–2015.((Epub ahead of print)).
PubMed/NCBI
|
